Pfizer (PFE) : Tuesdays money flow indicated an uptick to downtick ratio was at 1.09. The total value of inflow transactions on upticks was $23.14 million, whereas, the total value of outflow trades on downticks was $21.16 million. The total money flow was $1.98 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $1.13 million. The total value of the trades done on upticks was $2.18 million. Downticks saw transactions worth $1.05 million. The total uptick to downtick ratio stood at 2.08, mildly in favor of the bulls. Pfizer (PFE) was trading with a -0.51% change over previous days close. It fell $0.18 during the day and reached $34.93. The stock was 0.32% compared to the previous weeks close.
Also, Equity Analysts at the Jefferies maintains the rating on Pfizer (NYSE:PFE). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency lowers the price target from $41.5 per share to $40 per share. The rating by the firm was issued on August 4, 2016.
Pfizer Inc. has lost 0.6% in the last five trading days and dropped 5.74% in the last 4 weeks. Pfizer Inc. is up 1.21% in the last 3-month period. Year-to-Date the stock performance stands at 11.03%.
Pfizer (NYSE:PFE): The stock opened at $35.11 on Tuesday but the bulls could not build on the opening and the stock topped out at $35.18 for the day. The stock traded down to $34.85 during the day, due to lack of any buying support eventually closed down at $34.88 with a loss of -0.66% for the day. The stock had closed at $35.11 on the previous day. The total traded volume was 14,492,181 shares.
In a related news, Damelio Frank A, officer (Executive Vice President) of Pfizer Inc, unloaded 100,000 shares at an average price of $34.49 on May 26, 2016. The total amount of the transaction was worth $3,449,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.